Bioventus Inc. set terms Thursday of its initial public offering, in which the North Carolina-based joint pain and preservation company could raise up to $132.3 million and be valued at up to $976.2 million. The company is offering 7.35 million shares in the IPO, which is expected to price between $16 and $18 a share. The stock is expected to list on the Nasdaq under the ticker symbol "BVS." Bioventus expects there to be a total of 54.23 million Class A and Class B shares outstanding after the IPO.